Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

le.

The Company's unaudited interim consolidated first quarter fiscal 2009 and 2008 financial statements are summarized below:

    Consolidated Statements of Operations
    for the three month period ended October 31
    (thousand $, except for per share data)

                                              2008         2007
    Revenue:
      Product revenue                           921          754
      License fees and royalties                198          131
      Research and development
       contracts                                  -            -
                                              1,119          885
    Expenses:
      Cost of sales                             447          313
      Research and development                1,641          782
      Operating, general and admin            1,310        1,313
      Amortization of intangibles                 3            7
      Amortization of capital assets             64           66
      Stock-based compensation                    -           12
      Interest income, net                     (205)        (104)
      Foreign exchange loss                     150          108
                                              3,410        2,497

    Loss before income taxes                 (2,291)      (1,612)

    Income taxes                                 30           32

    Loss for the period                      (2,321)      (1,644)

    Loss per share:                           (0.05)       (0.05)
      Basic and Diluted                       (0.05)       (0.05)



    Consolidated Statements of Cash Flows
    for the three month period ended October 31
    (thousand $)



                                               2008        2007

    Cash provided by (used in):
      Loss for the period                    (2,321)      (1,644)

    Items not involving cash:
      Amortization of capital assets   
'/>"/>
SOURCE  Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Canna can: Ornamental eliminates pollutants from stormwater runoff 2Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Potential new heart attack biomarker uncovered 2Climate change could drive vast human migrations 8782 1Climate change could drive vast human migrations 8782 2Climate change could drive vast human migrations 8782 3 26amp 3B 238216 3BHairConfirm 26apos 3B Is First Drug Test of Its Kind to Report Low Medium High Usage 3B Now Available at Local Discount Drug Marts 48406 1 26amp 3B 238216 3BHairConfirm 26apos 3B Is First Drug Test of Its Kind to Report Low Medium High Usage 3B Now Available at Local Discount Drug Marts 48406 2 26amp 3B 238216 3BHairConfirm 26apos 3B Is First Drug Test of Its Kind to Report Low Medium High Usage 3B Now Available at Local Discount Drug Marts 48406 3New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 1New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 2New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 3New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 4New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 5